دورية أكاديمية
Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation.
العنوان: | Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation. |
---|---|
المؤلفون: | Lim JU; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Park S; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Yoon JH; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Lee SE; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Cho BS; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Kim YJ; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Lee S; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Kim HJ; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Rhee CK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. Electronic address: chinkook77@gmail.com. |
المصدر: | Respiratory medicine [Respir Med] 2023 Nov; Vol. 218, pp. 107410. Date of Electronic Publication: 2023 Sep 09. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 8908438 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3064 (Electronic) Linking ISSN: 09546111 NLM ISO Abbreviation: Respir Med Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2003- : Oxford : Elsevier Original Publication: London : Baillière Tindall, in association with the British Thoracic Society, [c1989- |
مواضيع طبية MeSH: | Bronchiolitis Obliterans*/drug therapy , Bronchiolitis Obliterans*/etiology , Hematopoietic Stem Cell Transplantation*/adverse effects , Pulmonary Disease, Chronic Obstructive*, Humans ; Tiotropium Bromide/therapeutic use ; Budesonide/therapeutic use ; Retrospective Studies ; Budesonide, Formoterol Fumarate Drug Combination/therapeutic use ; Bronchodilator Agents |
مستخلص: | Background: Bronchiolitis obliterans syndrome (BOS) is the lung manifestation of chronic graft-versus-host disease after hematopoietic stem cell transplantation (HSCT). We assessed whether inhaled tiotropium add-on to the combination regimen including budesonide/formoterol improve pulmonary function and the chronic obstructive pulmonary disease assessment test (CAT) scores in patients with BOS. Methods: Post-HSCT patients diagnosed as BOS in Seoul St. Mary's Hospital were reviewed retrospectively. Patients defined as BOS and treated with budesonide/formoterol/tiotropium combination therapy after budesonide/formoterol therapy from January 2011 to June 2019 were enrolled. Results: Total of 86 patients were evaluated. After tiotropium add-on, the absolute FEV1 increased significantly from 1.47 ± 0.49 to 1.53 ± 0.57 L (p = 0.023) and the % predicted FEV1 from 45.0 ± 12.8 to 46.8 ± 14.5% (p = 0.031). The % predicted DLCO increased significantly after tiotropium add-on (from 61.6 ± 16.7 to 64.3 ± 16.3%, p = 0.028). Among 56 patients with complete CAT scores, no significant change was present in total CAT scores. In all, 30 of the 72 patients (41.7%) evidenced FEV1 increases > 100 mL, and 20 of 56 patients (35.7%) had CAT score decreases of ≥ 2 points. When the FEV1 and CAT scores were combined, the overall response rate to tiotropium add-on was 56.2% (41/73). The response group evidenced a significantly greater FVC increase, and a significant decrease in the RV/TLC ratio compared to the no-response group. Conclusions: Inhaled tiotropium add-on to combination budesonide/formoterol significantly improved lung function, but not respiratory symptoms, in patients with post-HSCT BOS. Competing Interests: Declaration of competing interest CK Rhee received consulting/lecture fees from MSD, AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, Sanofi, and Bayer. All other authors also do not have competing interest. (Copyright © 2023 Elsevier Ltd. All rights reserved.) |
فهرسة مساهمة: | Keywords: Bronchiolitis obliterans syndrome; Chronic graft-versus-host disease; Hematopoietic stem cell transplantation; Lung; Tiotropium |
المشرفين على المادة: | XX112XZP0J (Tiotropium Bromide) 51333-22-3 (Budesonide) 0 (Budesonide, Formoterol Fumarate Drug Combination) 0 (Bronchodilator Agents) |
تواريخ الأحداث: | Date Created: 20230911 Date Completed: 20231103 Latest Revision: 20231114 |
رمز التحديث: | 20240628 |
DOI: | 10.1016/j.rmed.2023.107410 |
PMID: | 37696312 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1532-3064 |
---|---|
DOI: | 10.1016/j.rmed.2023.107410 |